NEXGEL, INC. (NXGL) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does NEXGEL, INC. Do?
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It provides facemasks, undereye patches, blister shield foot care, hexagel, cracked heel repair patches, and fever patch. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was founded in 1997 and is based in Langhorne, Pennsylvania. NEXGEL, INC. (NXGL) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Adam D. Levy and employs approximately 10 people. With a market capitalization of $5M, NXGL is one of the notable companies in the Healthcare sector.
NEXGEL, INC. (NXGL) Stock Rating — Avoid (April 2026)
As of April 2026, NEXGEL, INC. receives a Avoid rating with a composite score of 23.7/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.NXGL ranks #4,376 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, NEXGEL, INC. ranks among stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
NXGL Stock Price and 52-Week Range
NEXGEL, INC. (NXGL) currently trades at $0.55. The stock lost $0.07 (11.3%) in the most recent trading session. The 52-week high for NXGL is $3.25, which means the stock is currently trading -83.1% from its annual peak. The 52-week low is $0.70, putting the stock -21.8% above its annual trough. Recent trading volume was 63K shares, suggesting relatively thin trading activity.
Is NXGL Overvalued or Undervalued? — Valuation Analysis
NEXGEL, INC. (NXGL) carries a value factor score of 13/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.06x, versus the sector average of 2.75x. The price-to-sales ratio is 0.45x, compared to 1.66x for the average Healthcare stock.
At current multiples, NEXGEL, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
NEXGEL, INC. Profitability — ROE, Margins, and Quality Score
NEXGEL, INC. (NXGL) earns a quality factor score of 24/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -55.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -26.0% versus the sector average of -33.1%.
On a margin basis, NEXGEL, INC. reports gross margins of 43.0%, compared to 71.5% for the sector. The operating margin is -25.3% (sector: -66.1%). Net profit margin stands at -23.5%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 103.8% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
NXGL Debt, Balance Sheet, and Financial Health
NEXGEL, INC. has a debt-to-equity ratio of 12.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 1.47x, suggesting adequate working capital coverage. Total debt on the balance sheet is $588,000.
NXGL has a beta of 0.67, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for NEXGEL, INC. is 34/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
NEXGEL, INC. Revenue and Earnings History — Quarterly Trend
In TTM 2026, NEXGEL, INC. reported revenue of $12M and earnings per share (EPS) of $-0.38. Net income for the quarter was $-3M. Gross margin was 43.0%. Operating income came in at $-3M.
In FY 2025, NEXGEL, INC. reported revenue of $11M and earnings per share (EPS) of $-0.38. Net income for the quarter was $-3M. Gross margin was 39.5%. Revenue grew 31.5% year-over-year compared to FY 2024. Operating income came in at $-3M.
In Q3 2025, NEXGEL, INC. reported revenue of $3M and earnings per share (EPS) of $-0.08. Net income for the quarter was $-647,000. Gross margin was 42.4%. Revenue grew -0.2% year-over-year compared to Q3 2024. Operating income came in at $-725,000.
In Q2 2025, NEXGEL, INC. reported revenue of $3M and earnings per share (EPS) of $-0.09. Net income for the quarter was $-640,000. Gross margin was 43.6%. Revenue grew 100.3% year-over-year compared to Q2 2024. Operating income came in at $-636,000.
Over the past 8 quarters, NEXGEL, INC. has demonstrated a growth trajectory, with revenue expanding from $1M to $12M. Investors analyzing NXGL stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
NXGL Dividend Yield and Income Analysis
NEXGEL, INC. (NXGL) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
NXGL Momentum and Technical Analysis Profile
NEXGEL, INC. (NXGL) has a momentum factor score of 10/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 65/100 reflects moderate short selling activity.
NXGL vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, NEXGEL, INC. (NXGL) ranks #— out of 838 stocks based on the Blank Capital composite score. This places NXGL in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing NXGL against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NXGL vs S&P 500 (SPY) comparison to assess how NEXGEL, INC. stacks up against the broader market across all factor dimensions.
NXGL Next Earnings Date
No upcoming earnings date has been announced for NEXGEL, INC. (NXGL) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy NXGL? — Investment Thesis Summary
The quantitative profile for NEXGEL, INC. suggests caution. The quality score of 24/100 flags below-average profitability. The value score of 13/100 indicates premium valuation. Momentum is weak at 10/100, a headwind for near-term performance. High volatility (stability score 34/100) increases portfolio risk.
In summary, NEXGEL, INC. (NXGL) earns a Avoid rating with a composite score of 23.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NXGL stock.
Related Resources for NXGL Investors
Explore more research and tools: NXGL vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NXGL head-to-head with peers: NXGL vs AZN, NXGL vs SLGL, NXGL vs VMD.